Strains of lactobacillus hel veticus which do not ferment lactose
Patent Information
- Application Number
- LAP73
- Authority / Receiving Office
- LA · LA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2006-02-21
- Filing Date
- 2007-02-19
- Publication Date
- 2025-09-26
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[0001] New strains of Lactobacillus helveticus
[0002] The present invention relates to novel strains of Lactobacillus helveticus and their applications in the food industry. More specifically, the present invention provides strains of Lactobacillus helveticus with a lactose-reducing phenotype. The present invention also relates to a method for obtaining such strains of Lactobacillus helveticus.
[0003] Hypertension affects a significant portion of the population. The use of the VPP (Val Pro Pro) peptide and peptides containing the VPP sequence as agents capable of reducing blood pressure by inhibiting angiotensin-converting enzyme (ACE) was described in EP 0 583 074. A similar effect of the IPP (Ile Pro Pro) tripeptide has also been described in the literature. These peptides inhibit ACE by blocking its active site, thus preventing it from activating angiotensin.
[0004] It is known that both VPP and IPP sequences are present in bovine beta-casein and that the proper hydrolysis of this casein (or more generally, of the milk containing it) yields these tripeptides. Numerous animal and human studies have shown that daily ingestion of a few milligrams of these tripeptides effectively reduces blood pressure, particularly in hypertensive individuals, thereby reducing the risk of cardiovascular events.
[0005] Peptides from milk fermented by Lactobacillus helveticus have shown in vivo their inhibitory effect on ACE (ACEI) and these peptides have been found in the aorta of rats that participated in the study (Masuda O. et al., 1996. J. Nutr.
[0006] 126, 3063-8). Other studies have also shown more specifically a decrease in blood pressure in hypertensive rats following the ingestion of peptides from milk fermented by L. helveticus (Yamamoto N. et al., 1994. Biosci. Biotech. Biochem. 58, 776-8). In humans, the same fermented milk has also been shown to lower systolic blood pressure (Hâta et al.; 1996. Am. J. Clin. Nutr., 64, 767-71). A more recent study confirms that the peptides in the AMEAL S® product marketed by CALPIS significantly reduce blood pressure in subjects with higher than normal blood pressure.
[0007] (Mizuno et al., 2005. British Journal of Nutrition; vol 94, issue 1, 84-91). In another recent study (Jauhiainen et al.; 2005. Am. J. of Hypertension, 18: 1600-1605) it is hypothesized that the mechanism of action cited above (inhibition of ACE) to explain the antihypertensive effect of milk fermented with L. helveticus may not, however, be the determining mechanism of action in humans.
[0008] A large majority of Lactobacillus helveticus strains are capable of producing the tripeptides IPP and VPP through milk fermentation, but the quantities produced can vary. EP 1 016 709 describes a method for producing VPP and IPP tripeptides through milk fermentation using specific strains of lactic acid bacteria belonging to the species Lactobacillus helveticus. However, the resulting product (fermented milk) contains a very high amount of lactic acid and is therefore characterized by an unacceptable acidity from a sensory and gustatory point of view. Furthermore, there is the problem of post-acidification: even if fermentation is stopped (typically by cooling) at organoleptically acceptable pH levels (pH > 4), acidification continues in cold conditions due to the intrinsic properties of Lactobacillus helveticus. This leads to a drop in the product's pH, which then becomes equally unsuitable for consumption.To avoid post-acidification, it is possible to stop fermentation at an acceptable pH by immediately killing the strain by heat treatment.
[0009] (Pasteurization, thermization): post-acidification is then negligible (the product's acidity no longer changes during storage). Unfortunately, the quantity of tripeptides is reduced due to the early cessation of fermentation. The products thus obtained have only low levels of IPP and VPP. It is also possible to ferment the milk with the same starter culture until a maximum tripeptide concentration is reached. The large quantity of lactic acid generated in parallel must then It can be removed through a complex and costly multi-step process. Furthermore, the process is not "natural," as it involves separation steps. Therefore, such a process is not suitable for industrial scale.
[0010] The present invention offers solutions to the drawbacks of the prior art. In particular, the present invention offers strains of
[0011] Lactobacillus helveticus, which allows the preparation of food products, particularly fermented dairy products, possesses numerous advantageous properties:
[0012] The dairy products according to the invention have perfectly controlled acidity, not only at the end of fermentation but also during storage. In particular, they are not subject to post-acidification. Thus, the dairy products according to the invention are organoleptically very satisfactory. The dairy products according to the invention are directly consumable as probiotics, that is to say, they contain a significant quantity of live bacteria, without any impact on their taste qualities, and in particular, without any impact on their acidity.
[0013] The preparation of the products according to the invention requires no heat treatment step, nor any complex purification step. The processes according to the invention can therefore be implemented simply, in conventional dairy facilities, without significant equipment modifications.
[0014] Furthermore, the processes according to the invention are entirely natural.
[0015] - Food products, particularly dairy products, according to the invention can contain very high levels of VPP and IPP tripeptides, with high ratios of (IPP+VPP) / (lactic acid). These results can be obtained without a prior purification or concentration step.
[0016] - Food products, particularly dairy products, according to the invention advantageously contain a significant amount of biomass (i.e., a significant concentration of living microorganisms). For the purposes of this invention, a strain is understood to mean any culture, generally pure, of a microorganism, obtained from a single cell or an isolated colony.
[0017] For the purposes of this invention, a variant or mutant of a strain X means any strain obtained from a reference strain X. In this context, the terms "variant" will be used more specifically to refer to a strain obtained mainly by mutation and selection from a reference strain X, and "mutant" will be used more specifically to refer to a strain obtained by random or directed mutagenesis techniques (e.g., genetic transformation using vectors) applied to strain X.
[0018] Mutants or variants of the strains according to the present invention will, of course, be covered by the protection conferred by this patent provided they retain the essential aspects of the invention, in particular the lactose-negative phenotype. A strain with a "lactose-negative phenotype" is understood to mean any strain lacking the ability to convert lactose into lactic acid.
[0019] A strain with a "fructose-negative phenotype" is defined as any strain lacking the ability to metabolize fructose. A dairy medium is defined as any medium containing milk proteins, for example, standardized cow's milk containing 4% protein, combined with cow's milk powder (skimmed or whole) or concentrated milk.
[0020] For the purposes of this invention, a dairy product includes, in addition to milk, any product derived from milk, such as cream, ice cream, butter, cheese, yogurt, and fermented milk; secondary products, such as whey and casein; and various prepared foods containing milk or milk constituents as a main ingredient. Among dairy products, fermented dairy products include, among others, yogurts, fermented milks, soft cheeses, kefirs, cheeses, probiotic dairy products, and more generally, any dairy product that has undergone at least one fermentation step. This milk is generally cow's milk, but may also be the milk of other mammals, such as goats, sheep, mares, camels, and buffaloes. For the purposes of this invention, a food product is defined as any product intended for human or animal consumption. In particular, food products include products intended for feeding infants, children, adolescents, and adults. Food products according to the invention may contain, in whole or in part, at least one fermented dairy product according to the invention. Food products according to the invention may also contain other ingredients commonly used in the food industry, such as additives, preservatives, fruits or fruit extracts, flavorings, colorings, texturizing agents, cereals, chocolate pieces, etc. For the purposes of this invention, a starter culture is defined as any composition containing at least one live strain of microorganism capable of fermenting a given medium.Among the ferments, lactic ferments are compositions containing at least one live strain of microorganism capable of fermenting a dairy medium.
[0021] According to one embodiment, the present invention relates to a strain of Lactobacillus helveticus that lacks the ability to convert lactose into lactic acid. The present invention also relates to a strain of Lactobacillus helveticus that lacks the ability to convert lactose into lactic acid and possesses at least one mutation in the lactose operon.
[0022] According to one embodiment, the mutation in the lactose operon is a point mutation introducing a stop codon. According to a further preferred embodiment, the point mutation introducing a stop codon is located in the lacL gene of the lactose operon. A point mutation is defined as any nucleotide substitution occurring in the sequence, compared to a sequence known as
[0023] "Wild-type." A person skilled in the art can identify a stop codon (also called a nonsense codon), which generally corresponds in mRNA terms to one of the triplets: UAA, UAG, UGA. Thus, the Lactobacillus helveticus strains according to the invention do not have the ability to degrade lactose (no transformation of lactose into lactic acid). Indeed, the strains according to the invention have a lactose-negative phenotype. On the other hand, they are capable of growing in the presence of glucose as a carbon source (fermentation of glucose into lactic acid), and of metabolizing certain components of milk, including proteins.
[0024] Thus, the strains according to the invention advantageously allow fermentation at a fully controlled pH: the final pH after fermentation is perfectly controlled according to the quantity of glucose initially contained in the fermentation medium.
[0025] This is because a given quantity of glucose is converted almost stoichiometrically into the same quantity of lactic acid. Furthermore, the use of the strains according to the invention prevents any post-acidification. Thus, thanks to the strains according to the invention, it is possible to obtain food products that are particularly satisfactory from an organoleptic point of view.
[0026] Advantageously, according to one embodiment, the Lactobacillus helveticus strains according to the invention are such that a dairy medium with 4.0% total protein containing 1.0% (w / w) glucose fermented by said strains of
[0027] Lactobacillus helveticus during a maximum fermentation time of 30 minutes, at a temperature between 30 and 45 0 C, has a pH greater than or equal to 4.0; preferably greater than or equal to 4.1; preferably greater than or equal to
[0028] 4.2; preferably greater than or equal to 4.3; preferably greater than or equal to 4.5.
[0029] This advantage is therefore particularly marked in the case of Lactobacillus helveticus strains that are hyper-producers of IPP and / or VPP tripeptides: there is absolutely no need to choose a compromise between high tripeptide production during fermentation (requiring the longest possible fermentation time), and organoleptically acceptable properties (requiring limited acidification, and therefore, not only the shortest possible fermentation time, in order to limit the production of lactic acid by fermentation, but also thermization / pasteurization in order to avoid the post-acidification phenomenon). Indeed, advantageously according to the present invention, the production of VPP and / or IPP tripeptides, and the production of lactic acid are partially decoupled: the production of lactic acid is only a function of the quantity of glucose initially present in the fermentation medium, and no longer a function of the fermentation time.
[0030] A simple way to express tripeptide concentration is to express it as a positive pressure value (PPV) [PPVeq]. It is expressed in mg / kg: [PPVeq] = [PPV] + (9 / 5 x [PPV])
[0031] Thus, according to one embodiment, the Lactobacillus helveticus strains according to the invention are advantageously capable, by fermentation, of producing the tripeptides of sequence IPP and / or VPP in an amount of at least 25 mg, preferably at least 30 mg, preferably at least 35 mg, preferably at least 40 mg, preferably at least 45 mg, preferably at least 50 mg, preferably at least 55 mg, preferably at least 60 mg, preferably at least 65 mg, preferably at least 70 mg, preferably at least 75 mg, more preferably at least 80 mg of VPPeq per kg of fermented product.Such quantities of VPP and / or IPP are generally obtained by fermentation with a strain according to the invention at a temperature between 30 and 45°C, preferably between 31 and 44°C, preferably between 32 and 43°C, preferably between 33 and 42°C, preferably between 34 and 41°C, preferably between 35 and 40°C, and more preferably at 37. 0C, of a dairy medium containing a glucose content greater than 3% (w / w) and with a total protein content greater than or equal to 2% (w / w), preferably between 2 and 10% (w / w), more preferably between 2.5 and 6% (w / w), and even more preferably equal to 4% (w / w). According to one embodiment, the Lactobacillus helveticus strains according to the invention further possess a fructose-negative phenotype. The combination of the lactose-negative and fructose-negative phenotypes is particularly advantageous. Indeed, fructose has a strong sweetening power and is a useful ingredient in food products. Thus, if fructose cannot be degraded by the Lactobacillus strain When using *Symphytum helveticus*, the food product retains excellent organoleptic properties. Furthermore, a strain that is both lactose- and fructose-low will only grow in a glucose-containing medium. Therefore, the final pH will be advantageously better controlled when the food product contains a fruit preparation, particularly fruit pieces and / or juice.
[0032] According to one embodiment, the strain according to the invention is chosen from:
[0033] 1-3504 filed with the CNCM on 14 / 10 / 05;
[0034] 1-3505 filed with the CNCM on 14 / 10 / 05;
[0035] 1-3508 filed with the CNCM on 14 / 10 / 05; and variant or mutant strains derived from these.
[0036] According to another embodiment, the present invention relates to the use of a strain of Lactobacillus helveticus according to the invention, for the preparation of a food or pharmaceutical product, in particular a fermented dairy product.
[0037] Advantageously, according to one aspect of the invention, said food or pharmaceutical product possesses anti-hypertensive properties.
[0038] The present invention also relates to a food product, in particular a fermented dairy product, comprising at least one strain of Lactobacillus helveticus according to the invention.
[0039] Advantageously, according to one embodiment, said food product contains at least 10 6 preferably at least 10 7 preferably at least 10 8CFU / mL of live Lactobacillus helveticus bacteria. Thus, the food product according to the invention contains a significant amount of biomass. In one embodiment, said food product contains at least 25 mg, preferably at least 30 mg, preferably at least 35 mg, preferably at least 40 mg, preferably at least 45 mg, preferably at least 50 mg, preferably at least 55 mg, preferably at least 60 mg, preferably at least 65 mg, preferably at least 70 mg, preferably at least 75 mg, and more preferably at least 80 mg of VPPeq per kg of food product. In one embodiment, the food product according to the invention further comprises fruit preparations, in particular fruit pieces and / or fruit juice. According to one embodiment, the food product according to the invention has a pH greater than or equal to 3.85; preferably greater than or equal to 3.90; preferably greater than or equal to 3.95; preferably greater than or equal to 4.00; preferably greater than or equal to 4.05; preferably greater than or equal to 4.10; preferably greater than or equal to 4.15; more preferably greater than or equal to 4.20.
[0040] Advantageously, according to one embodiment, the food product according to the invention possesses anti-hypertensive properties.
[0041] According to another aspect, the present invention relates to a method for preparing a food product.
[0042] According to one embodiment, said process comprises the following steps:
[0043] "select a raw material containing milk proteins, in particular proteins containing the IPP and / or VPP peptide sequences. This could for example be milk containing 2-10% (w / w) of total proteins.
[0044] "to select at least one Lactobacillus helveticus strain according to the invention,
[0045] " inoculate said raw material with said strain, " ferment said raw material in the presence of 1-3% (w / w) of glucose for 12-30 hours at 30-45°C, and in the presence of said strain.
[0046] According to one embodiment, the process according to the invention advantageously eliminates any heat treatment step after fermentation. This allows live bacteria to be preserved in the food product (probiotic).
[0047] According to one embodiment, the present invention relates to the use of streptozotocin for obtaining Lactobacillus helveticus strains possessing a lactose-free phenotype.
[0048] The present invention also provides a method for obtaining such strains of
[0049] Lactobacillus helveticus. According to one embodiment, said process for obtaining Lactobacillus helveticus strains possessing a lactose-negative phenotype, comprising the following steps: "provide at least one strain of Lactobacillus helveticus;
[0050] "to expose said strain to an effective amount of streptozotocin in the presence of lactose; to isolate the lactose-negative phenotype colony or colonies. The population of Lactobacillus helveticus cells capable of surviving in the presence of streptozotocin is indeed advantageously extremely enriched in lactose-negative cells."
[0051] According to one embodiment, a colorimetric test step on a medium containing Xgal and / or Sgal and / or any other compound linked by a β-galactosidic bond to galactose and which becomes detectable following the breaking of this bond by the microorganism, is added to said strain production process according to the invention. IPTG can also be added to perform this test since this compound will act as an inducer of the lactose transporter or as an inducer of lactose utilization by the microorganism.
[0052] As an example, the said process can be carried out in the following manner:
[0053] First subculturing of the initial Lactobacillus helveticus strains (mother strains) onto neutral MRS (Man Rogosa Sharp) broth overnight at 35-40°C; second subculturing into neutral MRS broth. Incubation until sufficient biomass is obtained, for example, 10-30 hours at 35-40°C. 0 C.
[0054] - Inoculation of MRS containing a lactose concentration sufficient to obtain adequate biomass, for example 2-7% (w / w); incubation with OD monitoring at 580 nm. - Streptozotocin is prepared extemporaneously and added during fermentation to achieve a final concentration that is bactericidal for the strain in question. This concentration is strain-dependent. After incubation at 35-40°C, the cultures are washed twice with tryptone salt. - The pellets are resuspended in tryptone salt, and then neutral MRS broths are used for re-culturing. Incubation at 35-40°C 0 C, until the strain grows. - Isolations are then performed on MRSneutral + Xgal + IPTG, and then incubated at 35-40°C 0C under CO2. This step is a colorimetric test to determine if a bacterial strain is lactose-positive or lactose-negative: If the strain is able to use lactose as a carbon source, a blue substance is produced, and the colony will therefore be blue; otherwise (lactose-negative strain), it will be white. White colonies are subcultured onto neutral MRS and incubated at 35-40°C. 0 C.
[0055] The invention will be further described with the aid of the following examples, which are not limiting.
[0056] EXAMPLES OF ACHIEVEMENTS
[0057] EXAMPLE 1: Obtaining strains with a lower lactose phenotype
[0058] Materials and methods
[0059] Starting strains (so-called "mother" strains)
[0060] 1-3431 filed with the CNCM on 25 / 05 / 05
[0061] 1-3434 filed with the CNCM on 25 / 05 / 05
[0062] 1-3435 filed with the CNCM on 25 / 05 / 05
[0063] Streptozotocin sensitivity test
[0064] Initially, the sensitivity of the parent strains to the antibiotic used, streptozotocin, is verified. The optical density (OD) at 580 nm is monitored on cultures at 42°C in neutral MRS (Man Rogosa Sharp) broth. When it reaches 0.1, streptozotocin is added to a tube to obtain a final concentration of 50 μg / ml (for example, 100 μl of a 5 mg / ml solution per 10 ml of medium). Selection of lactose-negative strains: The following steps are carried out to obtain lactose-negative Lactobacillus helveticus strains:
[0065] - First subculturing of the starting Lactobacillus helveticus strains (mother strains) from the wells of the working stock, onto neutral MRS broth, overnight at 37 0 C; - 2nd transplant at 1% in neutral MRS.
[0066] - Incubation 16h at 37°C.
[0067] - Inoculation of 10ml of MRS at 5% (w / w) lactose, at 1% and incubation at 40 0 C with monitoring of the OD at 580nm. - Streptozotocin is prepared extemporaneously, and is added after 2hl5 or 4h of fermentation, so as to have a final concentration of 50μg / ml.
[0068] - After 7.5 hours of incubation at 40°C, the cultures are washed twice with tryptone salt.
[0069] - The pellets are taken up in 2 ml of tryptone salt, then MRSneutre broths are inoculated at 10%.
[0070] - Incubation at 37°C, until the strain grows.
[0071] Isolations are then performed on MRSneutre + Xgal + IPTG, and then incubated at 37 0C under CO2. This step is a colorimetric test to determine if a bacterial strain is lactose plus or lactose minus: If the strain is able to use lactose as a carbon source, there is production of a blue substance, the colony will therefore be blue and in the opposite case (lactose minus strain), it will be white.
[0072] - The white colonies are subcultured onto MRSneutre and incubated at 37°C. Results: This allowed us to obtain the following strains, possessing a lactose-negative phenotype, which were then deposited with the CNCM (National Collection of Microorganism Cultures), 28 rue du Docteur Roux, 75724 Paris, France, in accordance with the provisions of the Budapest Treaty:
[0073] 1-3504 filed with the CNCM on 14 / 10 / 05; derived from the parent strain 1-3431
[0074] 1-3505 filed with the CNCM on 14 / 10 / 05; derived from the parent strain 1-3434
[0075] 1-3508 filed with the CNCM on 14 / 10 / 05; derived from the parent strain 1-3435
[0076] The lactose-negative phenotype of the strains obtained is again confirmed on a neutral MRS agar + Xgal + IPTG medium (so-called "white / blue" color test).
[0077] EXAMPLE 2: Strains possessing a lactose-negative phenotype Strain 1-3504, deposited on October 14, 2005, with the CNCM (National Collection of Microorganism Cultures), 28 rue du Docteur Roux, 75724 Paris, France, in accordance with the provisions of the Budapest Treaty, is a strain of Lactobacillus helveticus possessing the following properties: - Lactose-free; Fructose-free
[0078] - Production of IPP and VPP: see Figures 4 and 5
[0079] - Acidification properties: see Figure 1
[0080] - ACE inhibition: see Figure 6
[0081] Strain 1-3505, deposited on 14 / 10 / 05 with the CNCM (National Collection of Microorganism Cultures), 28 rue du Docteur Roux, 75724 Paris, France, in accordance with the provisions of the Budapest Treaty, is a strain of Lactobacillus helveticus possessing the following properties: Lactose-free; Fructose-free; IPP and VPP production: see Figure 5; acidification properties: see Figure 2
[0082] Strain 1-3508, deposited on 14 / 10 / 05 with the CNCM (National Collection of
[0083] Microorganism Cultures), 28 rue du Docteur Roux, 75724 Paris, France, in accordance with the provisions of the Budapest Treaty, is a strain of Lactobacillus helveticus possessing the following properties: - Lactose less; Fructose less
[0084] - IPP and VPP production: see Figure 5
[0085] - Acidification properties: see Figure 3
[0086] 1. Measurement of the acidification properties of the different variant strains. The acidification properties are evaluated as follows:
[0087] A medium containing 120g of skimmed milk powder (SMP) in 930ml of water is pasteurized for 10 minutes at 95°C. This medium is inoculated with 0.5% glucose and then fermented at 37°C in the presence of varying glucose concentrations. (The abbreviation Gx indicates a glucose concentration of x% (w / w) in the medium before fermentation). The pH is then monitored over time for different strains. A sample of the fermented medium taken after 30 hours of fermentation will be used for the production measurements of IPP and VPP tripeptides as well as for ACEI activity measurements, the results of which will be given below.
[0088] For 1-3504, the results of the parent strain (1-3431, lactose plus strain) are also presented (see Figure 1). For 1-3505, the results of the parent strain (1-3434, lactose plus strain) are also presented (see Figure 2).
[0089] For 1-3508, the results of the parent strain (1-3435, lactose plus strain) are also presented (see Figure 3).
[0090] The results presented in Figures 1-3 show that the strains according to the invention advantageously allow for precise control of the pH at the end of fermentation, depending on the initial amount of glucose present in the medium. Furthermore, fermentation with lactose-reducing strains advantageously leads to high pH values, resulting in organoleptically acceptable food products.
[0091] 2. Measurement of IPP and VPP tripeptide production
[0092] Materials and methods
[0093] A sample of dairy medium taken 30 hours after fermentation, as described previously in point 1, is used to perform this measurement. The analysis of peptide content, in particular the tripeptide content IPP and VPP, is carried out using HPLC liquid chromatography coupled with an MS / MS detector as described below:
[0094] - Due to the interferences inherent in the analysis of complex samples, the use of deuterated internal standards added in known and controlled quantities at the time of sample preparation is strongly advised.
[0095] - Sample preparation is carried out by diluting the fermented medium in a mixture of water, methanol, and trifluoroacetic acid (50 / 50 / 0.1%), containing 25 ppm of deuterated VPP internal standard (hereafter referred to as VPPd, formula H-VaI [D8]-Pro-Pro-OH, MM = 319.45 g / mol, available from Bachem Chemicals, France) and 10 ppm of deuterated IPP internal standard (hereafter referred to as IPPd, formula H-IIe [DlO N15]-Pro-Pro-OH, MM = 336.2 g / mol, available from NEOMPS, Groupe SNPE, 7 rue de Boulogne, 67100 Strasbourg, France) in a ratio of 1 to 3 (for example, accurate weighing in an Eppendorf of 600 mg of sample in 1200 mg of water-methanol-TFA mixture containing the internal standards).
[0096] - This diluted sample is then centrifuged at 14000 g for 15 minutes. The clear supernatant obtained, containing the peptides generated during fermentation, is then precisely diluted 1 / 50th in a water-methanol mixture (50 / 50, v / v) containing 0.1% trifluoroacetic acid.
[0097] The resulting diluted solution is then analyzed in an Agilent 1100 HPLC system (Agilent Technologies France, 1 rue Galvani, 91745 Massy Cedex, France), equipped with a column suitable for peptide analysis, a Waters Biosuite® (3 mm x 2.1 x 150 mm, Cl 8 PA-A, WATl 86002427, Waters France, 5 rue Jacques Monod, 78280 Guyancourt, France) at a temperature of 50°C and a flow rate of 0.25 ml / min. The peptides are eluted conventionally with an increasing gradient of solvent B (acetonitrile + 0.100% formic acid) in solvent A (water + 0.106% formic acid), over a period of 35 minutes to 2 hours, depending on the desired chromatographic resolution. The method adapted for the assay of IPP and VPP peptides uses the following gradient:
[0099] Detection is performed using a specific MS / MS detector, for example with an ion trap instrument such as the Esquire3000+ (Bruker Daltonique, rue de l'Industrie, 67166 Wissembourg Cedex), configured for positive electrospray ionization, either for global analysis of peptide content (MS-MS mode) or for precise and specific quantification of a peptide from its fragments. Characteristics (MRM mode). In the case of the assay of IPP and VPP peptides, as well as the internal standards IPPd and VPPd, these peptides are isolated from their specific mass (single-charged ions: 312.2 Da for VPP; 326.2 Da for IPP; 320.2 Da for VPPd; 337.3 Da for IPPd) and quantified from the intensity of their specific ions after fragmentation (fragments ≥ 85 Da). The integration of the chromatographic peaks of each of the IPP and VPP peptides and their comparison to the peak areas of the internal standards of known concentrations, IPPd and VPPd, then allows the initial VPP and IPP content of the sample to be calculated by simple linear regression (generally expressed in mg / kg or ppm). Results
[0101] Figure 4 shows a comparison of the production of IPP and VPP tripeptides of strain 1-3504 (2% (w / w) glucose is added to the medium) against two prior art strains.
[0102] The CM4 strain from the company CALPIS is described in patent EP 1 016 709 while the CRNZ 244 strain is described in patent application WO 2004 / 060073.
[0103] It is clear from this figure that strain 1-3504 (strain according to the invention) has a production of IPP and VPP tripeptides much higher than these two previous strains under the same conditions.
[0104] Figure 5 shows a comparison of the production of IPP and VPP tripeptides of the strains according to the invention between them.
[0105] 3. Measurement of ACEI (Angiotensin-Converting Enzyme Inhibition) Activity: Materials and Methods
[0106] A sample of dairy medium taken 30 hours after fermentation, as described previously in point 1, is used to perform this measurement. The present method has based on the method of Cushman and Cheng (Cushman et al. Biochem. Pharmacol. 1971. 20:1637), adapted to make it compatible with samples of fermented dairy products.
[0107] 1. Preparation of reagents and solutions 1.1 0.1M sodium borate buffer pH 8.3, supplemented with 0.3M NaCl
[0108] Weigh 6.1843g of H3BO3 (Carlo Erba ref: 402 766). Dissolve in approximately 800 ml of demineralized water, adjust to pH 8.3 with a NaOH solution, then add 12.0 g of NaCl (final concentration 0.3 M) and make up to 1 litre with demineralized water.
[0109] 1.2 Preparation of the HHL substrate: 5 mM Hip-His-Leu solution in 0.1 M sodium borate buffer pH 8.3 with 0.3 M NaCl
[0110] Weigh out exactly 42.95 mg of anhydrous HHL peptide (N-Hippuryl-Histidyl-Leucine tetrahydrate Wt.: 501.5 g, Sigma-Aldrich ref: 53285-250 mg) and dissolve in approximately 15 mL of 0.1 M sodium borate buffer pH 8.3 with 0.3 M NaCl, then make up to 20 mL with the same buffer. 1.3 Preparation of the ACE solution at 0.1 U / mL
[0111] Angiotensin-converting enzyme (ACE) in lyophilized powder form (origin: rabbit lung, Sigma-Aldrich ref A6778, 0.25 units) is dissolved in 2.5 mL of 0.1 M sodium borate buffer, pH 8.3, to obtain a 0.1 LV mL solution. The prepared solution should be used and stored at 4°C for a maximum of 2 weeks to maintain sufficient enzymatic activity.
[0112] 2. Preparation of fermented milk samples
[0113] It is necessary to condition the sample at a pH between 8.0 and 8.5 so as to be close to the optimal pH of ACE. The fermented milk is first centrifuged, the pH of the supernatant is then adjusted between 8.0 and 8.5 (ideally pH 8.3) and then ultrafiltered using a Vivaspin filtration unit with a cut-off threshold of 10,000 Daltons (Vivascience, France) in order to remove interfering elements (whole proteins, calcium salts).
[0114] The complete protocol is as follows: - Place approximately 6 mL of fermented milk into a 15 mL Falcon tube after first weighing the empty tube. Weigh the amount of fermented milk placed in the tube.
[0115] - Centrifuge at 14,000g for 10 minutes at 10 0 C. - Recover the supernatant
[0116] Quantify the pellet / supernatant proportion, which allows, if necessary, the determination of TIC50 equivalent to the original product and not just its supernatant.
[0117] Take 2.0mL of supernatant in a test tube and measure the pH.
[0118] - Add the required volume of 2M NaOH to obtain a pH between 8.0 and 8.5 (target: 8.3) after adding the borate buffer, then stir.
[0119] Add the required volume of borate buffer to dilute the initial supernatant to 1 Taking into account the exact volume of NaOH added (for example: supernatant test portion = 2mL + 250μL NaOH + 1.75mL borate buffer)
[0120] - Check that the final pH is between 8.0 and 8.5. If it is higher, repeat the process, adding more or less NaOH. A precipitate will form: this is due to the calcium salts.
[0121] Ultracentrifuge the sample at 12,000 g for 15 min at 10 0 C. Using Vivaspin 10,000 Dalton filtration units (capacity 4-6 mL) to obtain a clear sample. 3. Measurement of ACE inhibition by fermented milk samples
[0122] For each series of analyses, control samples (0 and 100% ACE activity) must be prepared. For each sample, two independent tests and a blank sample are performed for each dilution. It is essential to adjust the amount of sample required to reduce ACE activity by 50% as closely as possible (by diluting it).
[0123] For that :
[0124] Add 80 μL of the sample conditioned at pH 8.3 to the white tube and to the test tubes
[0125] - Add 80μL of demineralized water to the 0 and 100% control tubes. - Add 200μl of the 5mM HHL substrate solution to all tubes. Shake. - Place the tubes in a water bath thermostatically controlled at 37 0 C, allow to equilibrate temperature
[0126] - Trigger the enzymatic reaction by adding 20μL of ACE solution at 0.1U / mL to each tube, except for the sample blanks and 0% control for which 20μL of borate buffer pH 8.3 must be added.
[0127] - Allow to hydrolyze for exactly 1 hour at 37°C.
[0128] Stop the reaction by adding 250 μL of IM HCl solution to each tube. Summary table of the composition of the different reaction media:
[0130] The reading is done by extracting the hydrolyzed substrate (hippuric acid) and quantifying it using a spectrophotometer, with the following protocol:
[0131] Add 1.7mL of ethyl acetate to each tube and shake.
[0132] Centrifuge at 2000g for 5 minutes at 10°C
[0133] Collect ImL exactly from the supernatant in an Eppendorf microtube
[0134] Evaporate the ethyl acetate at 120 0C for 10 minutes in a heating block
[0135] Add exactly 1ml of demineralized water and then stir for 10 seconds to reabsorb the hippuric acid.
[0136] Read the absorbance at 228 nm in cuvettes adapted for UV reading
[0137] Expression of results:
[0138] The percentage of ACE inhibition is calculated as follows:
[0139] (Abs 100% ctl - Abs 0% ctl) - (Abs ech - Abs white ech) x 100 (Abs 100% ctl - Abs 0% ctl)
[0140] With Abs = absorbance at 228 nm after hippuric acid extraction, ctl = control ech = sample
[0141] For fermented milk, we express PIC50 as the amount of supernatant of this fermented milk that inhibits 50% of the enzymatic activity of ACE in the reaction medium, i.e. in microliters of fermented milk supernatant per milliliter of reaction medium.
[0142] Results
[0143] Figure 6 shows a comparison of the angiotensin-converting enzyme (ACE) inhibitory activity of different strains according to the present invention compared to other prior art strains. The y-axis represents the equivalent concentration of fermented milk per mL of reaction medium required to inhibit 50% of ACE activity (IC50). The higher this concentration, the lower the strain's ability to inhibit ACE.
[0144] EXAMPLE 3: Preparation of a dairy product (probiotic) according to the invention
[0145] A fermented dairy product is obtained as described below. Large-batch milk, previously skimmed, pre-pasteurized and cooled to 4 0It is standardized in protein (4.0%) with skimmed milk powder and supplemented with glucose at a rate of 1.8% (w / w). The resulting dairy medium is pasteurized (95°C - 8 min). After cooling to 37 0 C The dairy medium is inoculated with a strain according to the present invention at a rate of 10 7 CFU / mL and maintained at 37 0 C throughout the fermentation process. When pH 3.8 is reached, the curd is removed from the fermentation tank to undergo smoothing (by passing through a filter) and cooled to 10 0 C in a plate heat exchanger. The smoothed and cooled curd is then mixed with a fruit preparation (having a pH between 4 and 4.1) at a rate of 15% of the finished product, packaged in 110 mL bottles and stored at 4°C for 28 days.
[0146] The product thus prepared contains IPP / VPP sequence tripeptides at a concentration of 65 mg / kg VPP equivalent. The peptide content of the product is advantageously stable throughout its shelf life. The decrease in pH during refrigerated storage is advantageously negligible (less than 0.1 unit) and the population of strains according to the present invention, advantageously remains between l0 7 and l0 8 CFU / mL.
[0147] EXAMPLE 4: Identification of nonsense point mutations in the lactose operon of strains according to the invention
[0148] From the lactose operon sequences of strains DPC4571 and ATCC15009 available on GenBank, oligonucleotides (primers) were selected from genes that appeared to be the most conserved. These oligonucleotides were used to perform a long-range PCR, and then to begin sequencing the lactose operon of strains according to the invention. The sequencing was then carried out step by step; that is, depending on the sequences obtained, other primers were used for further sequencing reactions.
[0149] A nonsense mutation has been identified in strain 1-3504 compared to the parent strain 1-3431: in the 5'-3' direction, a cytosine base is replaced by a thymine base, resulting in a stop codon 1320 base pairs from the start codon of the lacL gene (which is approximately 1900 bp) encoding β-galactosidase. Apart from this mutation, the lactose operons of the two strains 1-3431 and 1-3504 are identical. Sequence of the lactose operon of strain 1-3431 (framed mutation) aaatgaaaattcatgatctaactctggattaatgtgataagcgctttcaacatcagtgccccagctgtcaattcctccaacgccgcg aactgcacctgcaattactaacacggttctgcgaacaagtggtagttcttcaatgttagtagcgttctcaagctcctcagcagtata aggcaaacaactgaaattaaatggtttttctgcttgttgaattgagagactgaacttttcatttgtacgatctacattattttgtgtggtttc acgattaatggttaacttcttagtttgcatgtgcattccattttcctgcggaaccaaatactcggtaactggcaaaccatcgatatgga atttaccttctttagctccagccattctatcaggataagtttcaccggataaaccttcataatcaaatcctgtagcagccgttggcataatcaatcgaataccaattacaggcaggggtggtaatcccttcttaccataataacgcattgtaaccttaatgtgaccgacatcatc aatattatagatgatttttgcatttgttgcaggagtagttaaagtttgataggtaaatgaaatttcagcactttttgcatactcgtgattgct aaatttgttgttaaagggtgcaataggcagttcggcaaagtcatgtctgtctacttttaaatggatatcagtacatttagtaaacatat cagctccgagccattgagctgcctttagattaaatccactgcctcggtcgttatctgtagttgctcgccaaaaagtaggagtaggta cacgataaagccattccttgccgtgtacttttaacgattcaagtccgccgcgttcataactaaagatgtattgaaaatctttgccatta acgccaaatgtggcatccccataaatgatatgcaattgattatttgtgtgtaatccataatagtatctcacttcctgcatagctggttttggt tttctatctgcgaacattaaaccatcgccagaaaattcataatctgaatgacgatcatcaaaattgccgccataacgcaaaacat catgtccactaatttcatcatgaaccaataatgcctgatcgataaagtcccagataaatccaccgaagtattgagggtatttatcaa gtaatttgatatatgaatccatgccgccgttagaattgcccatgtcatgcatatattcgcattccataaatggctttggtggatcattttg caagtattcttcaacctttttaggtggtaaatacatacagctttcaacatctgaaattttatcttttaattcgggacggtgcactacgcctt catagtgaactaagcgtgtatcatcgtgagatttgtaaaattcattcattgcgatgatgttgtctctccagcataggattcgttgccaagtgaccaaaagagaatagaggtgtgattcttgaaagtctcgtagttattgcgtgctcgatcaatcactgcttctttc§attgcggaatcg aacctggtacattgtcagaaggttcaatctctcccattttttgccaagtaccatgtgattcaaggttattctcggccatgacataaatg ccattttgatcgcaaagataataccacggaatttggtttgggtagtgacatgttctaacagcattaatattattttctttaaaagtattaa tgtcagttgtcatatcactcattgttatgctgcgaccacgttttgcatcccattcatgtcggttaactccattgataattaaacfgcttgcca tttaacaaaacaactttttctggactaatttcaattctcctaaagccaaattggaaaggaatcagctctagcaagttttgttgttcatca taaacttcaattagaagctgataaaagatatggatcatggttattccaaaagatgcacgttttcgaatttttcattattaatttgaacgttctc tttgatatcttcattttctccagaagagtatgtcccttaatatctttgactaataaatggaatgaaccggatttttaccaataaaatgaa gcttaaggttgaagatgccatcttgataattatctgcaactcgtggtttcaaatccatgtccattaagtgggtagcggggatacctag tagttcaactgagcggaagatgccagagaagcggaacatgtcttggtcttctagccaagatgcagtactgtgtttaaaaacttcta ctgctaaaagattatcttttcttgaatatatggcgttaaatcaaattctgaaggagtaaagctgtcttccgcatagcccacaaaatg cccgtttaaccatacatacattgctttttcgacgccttcaaatttaatatgaacctttttttttttcttgaatataatggcgttaaatcaaattctgaaggctgaagcttaatcaatcg cttcaagtatgaaccgactgtgttatctgcgcctttgctaaatgagccttcttcatgatcattaggatctaaagcgtaagctgggcgg cggagaattttgccttcccaaggaaggaggacattaatatattgatttgagatagatttgctcaattcgattcacttggaactgggat cgaatcaaaaatttgaagaatcaaaaatcacgctgataaaaatcttgtggacgatccataggatagcggaaaaatgaaatttccat ttccatttaaactttgttgatagctactgtgttgccactggcgataatctcttaaaaaaggatgatcactgtgtgcgggcaatt gattgaccctgaatacctcaggattatctagccaattgatattgcttgcataatatgacctcatttctattaaaatatattcgaaagcgcttttattatagcatgtaaataaacaatttattagtattagtaaagaatttatttacaatatttaataagatttacttgctataaagactg aatacatgcagataatagaacctttatttattggaatttagtaaatattttgtataataaagaaagagaatttataaaaatagaaaag aaataattatgagaacaattaaagaaattgcgctggaatcaggctattctccagcgacagtatcacgtttattaaataatgatccta atttgtctattactgcagataccaaaaataagattttggagattgctaataaattgggctattgggaagatcatcaagaaaagaaa atcaagcccacaattgctttactttatcgagtaaatcataaggaacaattgcaggatgagtatttcacttcgttgaaacaagcatta gtttcaactgtagagcgagatgcgctgaagatgaaaaacttttatgacatagaagatttaatcaagaacgcttctttgttccaagga tttattggagtaggggcggagccaattgaaaacgcccagttggttaagctgcataaagttttgcctaatggtgtttttgttgataccaa tccagctcccgaattatttgattcaattcgccctaatctgcctcttacggttaaaaatgctattgatttgtttatcaaaaatggcattaac aagatcggttttatcggtggcgttggccctaagcatgaccatattcaggaaaaagatttgcgttcaattacttttgttgaatacatgaa aactagaggcatggatactaaatggacatgcgttgaaggaccggttagcgttgaaaatggttataaattgggaaaaatggttttg gctaaatacaaaaatgatttacctgaagcatttttaattgcatctgatactttagccgttggcgttttacaagcctttaacgaagaaaacgtaaatgtaccaaaagatactaagatcttaagtattaatatagcaatgtggttaagtatgttttcaccactttcttcgttcaaca ttaatcaaagaaatgattggcacttgatacttgactcatttgattattcatccagatcgaccaaagattgatatccggatg aacactaatttggtagtacgaaaaagcttcgttccccaagaaaagtaaatttttagtaaaaaatattttttgatagaaaataaa aagagaatgtgaacagctcacattctttttacttagttaaaaggagcgtatgactttcattgcaaacgattgcagagatt cattggggaggaaggaaaagatgaataatcataaaatctcaggaaagcaagtcatttcctatgcgtccttttgtggggggaattt aggatacgcagctttttatggcgtaatgagtacgtattttattatttatcactagtgccatgtttacaggactagatcattcagttgcag ataagttaattggcttaattactgcattgatagttttagtaagaaattgtagagttagtaattgatccagtgttggggaacatcgttgat aatactaaaacaaggtgaggcaagtttaagccttggatctttattggaacggtagctagtgccgcattactgctaattctctttactg "gtattttcggcttggcacataagagttggattctttttgcaattttatttgtaatcatttatatcggttttgacgttttttattccttatcagatgg ggcatggttccagccttaagtgaggattcacacgcacgtggtatttatactgctttggggactttttcaggtgcaattggttggaacg gactaactatcattgttgtgccactggttaccggtgtaacttatgcaatgactggcaagcatgaagaaggggctcctggttggtttg cctttgcggcggttatttcagccttagctattctttgtgcactaatcgtatgtttaggaactaatgaaaaacataatttaattagaaattct gccaagtaaaaaacaactttaggtcaagtatttggggcaatttcacataatgatcagattttatagccaagtttggcttatttgatgttc tcattggctaatgtaattacaaatggggtaatgttttatctgtacaaattcgtgattaataaaccaaatgacttctgggttgttggtgtca ttgccacattaatcgttttttgcattagtccattgtttccaattttaaataaatatattccaagaaaatggctatttattggcggtcaaatttg tatgattttggcatacgggttgttcattttcggtcgcaataacgtcattttaatggatttagggttagctctatttaatatcaactttgctcaa ttagtaactgttttaacattaactgatgccatcgaatatggtcagctgaaaagtggtcagagaaatgaagccgtcgttttagctgttc gaccaatggtcgataaatttaccggtgctatttcaaacgcgctagtaggatatgtagcaattgcggcaggcatgactggttcagcaactgcagcagatagacaagtcacgatattagcattttcaatattatggctttatatgtgccattaattttggcagttttagctattatcat ttttataagcaaggtaactttatctgaaaagaaacacgctcaagtggttgaagaattaaagagcaaacttgcacaagggaagat cgaagatggcaatttacctgcagcaaatttaaagtcgactgccatttatgcacctgcagatggtaaattaatgactatgtctgaagt aatcgatgaaaatggcaaaacatttcctggtaaaggctttgcaatcgatccaagcagtgggcaaatttttgccacatttgatggta aaattaagtttacctttggtaccaagcatgcgtttgaaattgtaactgaaaatggtctgcaagttatagttcacgttggtcttggcaca gttaatttgcgtggtgaaggatttgagtcatattatgatgatggacaaattgttaaaaaaggtgaactgctattagaatctgaccgtg atttagcactaaaaaatggttataaagatacgatagtaattttctatactcaacctggtatagtagaaaaaatgagtaaaatttcgg caggtaaagttgttgaacatggtcaaaaggtggttgaagtgaagtttaagtagaggaaactgatgtaagcataaatttaatattga tttacatgtataaaaaagaatgacttttagtgttaagtaaactttttggtaaagaaaaaattttataagcctttttttttaaaaaaagaatg acgtaaataagccttttctttaaatatttatacttagtaaatagcttagtaaatctaaataaatattttactagaacaaaaaaaaatgat aaattatttcgtgtaagcgatttctgaaaaggaatcttgggaggaattatcatgcataatcataaagtttcggggaaacaaatagtttcctatgcatcattttgtctgggcaatttggggcactcagcattttatggtgtaatgagtacatattttattatttttattactagtggaatgttt agcggattaaatcaatccgttgctgataaattagtaggtttaattactggattaatggtactagtaagaattatcgaactagtcattga ccctatttttgcagcattattacttattctatttactggtatttttggattagcacaacagaattggatcctttttgcaattttgtttgtgttgattt acatcgcttttgatgttttctattcattatcagatgtttcatattggggcatggttccagctttgagtgaagattcacatgaacgtggtattt atacttcacttggtgccttttcaggtactattggttggaatagtttgccaattattgttgtgccactggttaccggtgtaacttacgcggtt actggcaaacacgaagaaggagctcctggctggttcgcctttgcggccgtaatttcagccttagcaattatttgtgccttgattgtttg ctttggtactaaagaaaagcacaacattattagaaattcggccaaacagaaaaccactttgcgtcaagtatttggtgcgattttcc ataatgatcaaattttgtggccaagtttagcttacttattgtattcacttgctgttgtaattactaatggtgttttgttctacatgtacaagttt gtaattggcaagccaaatgatttctgggtagtaggtgtaattgcaacaattattggttgctgcattagtccatctttcccggttttgaac aaatatattccaagaaaatggttgtttattgcaggccaaacttgtatggtattagcatatgtcctatttatctttggtcgtaacaatgtctt cttaatggatttaggcttagttttattcaatattaacttcgctctgttggtaactgttttaactttaactgatgctattgaatatggtcaactta agattggtcaaagaaatgaagccgttgttttagctgttcgtccaatgattgataaatttactggtgctgtttcaaatgccttagttggtta tgtggcaattgcagctgggatgactggatcagctactgcagcagatatgacgagcaaaggtattaacacatttaatattatggcttt atatattcctttagctttggcagttttatctattgtagtatttttgagcaaagtaactttgagtgaaaagaaacacgcacaagttattgaa gaattgaagagtaaacttgcacaaggcgagattgaaaagaagacttcagtagatacaggaacaaaagaagtaactatttatg cacctgctgatggtgaattaatgcaaatgtcttctgttgttgatgaagatggtaaaccattccctggtaaaggatttgcaattgagccaagcagtggtcaaatttatgcaccatttgatggaacgatcaagtttactttcggtacaaagcatgcattcgagattgtgtcacaaaa tggactacaagttgttgtccatgtaggattgggtactgtcaatttacgtggagaaggctttgaaactttctacgatgatggtcaaaca gtgaaaaagggcgataaattacttgagtttgatcgtgatttggctcttaacaatggttataaagacacgatcgtgatattctatactc aaccaggtagaattcaaaattctggtgctattcaagctggtaaagatat
[0150] Similarly, sequencing analyses reveal the following mutations in the lactose operon of strains according to the invention:
[0151] - Strain 1-3505 compared to strain 1-3434: In strain 1-3505, an adenosine base replaces a guanine base which causes the appearance of a stop codon, 1713 base pairs from the beginning of the lacL gene encoding betagalactosidase.
[0152] Strain 1-3508 compared to strain 1-3435:
[0153] In strain 1-3508, an adenosine base replaces a guanine base, causing the appearance of a stop codon, 183 base pairs from the beginning of the lacL gene encoding betagalactosidase.
[0154] * * *
[0155] Applicant's or agent's file reference: GBU / CLY / BCT070044 International application no.
[0156] INFORMATION RELATING TO A MICROORGANISM OR OTHER BIOLOGICAL MATERIAL DEPOSIT
[0157] (PCT rule 130w)
[0158] A. The indications relate to the microorganism or other biological material referred to in the description on page A. Λ, line _
[0159] B. DEPOSIT IDENTIFICATION Other deposits are listed on a separate sheet
[0160] Name of the deposit institution
[0161] NATIONAL COLLECTION OF CULTURES OF MICROORGANISMS (CNCM)
[0162] Address of the depositing institution (including postal code and country)
[0163] Pasteur Institute, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France
[0164] Filing date, order number
[0165] May 25, 2005 CNCM 1-3431
[0166] An additional sheet is attached.
[0167] C. ADDITIONAL INFORMATION (if applicable) for the continuation of this information
[0168] CERTIFICATE OF DEPOSIT.
[0169] D. DESIGNATED STATES FOR WHICH INDICATIONS ARE PROVIDED
[0170] (if the information is not provided for all designated states)
[0171] E. INFORMATION PROVIDED SEPARATELY (if applicable)
[0172] The information listed below will be provided later to the International Bureau (specify the general nature of the information, e.g., "n" of the filing order).
[0174] Form PCT / RO / 134 (July 1998; reprinted January 2004) Applicant's or agent's file reference: GBU / CLY / BCT070044 International Application No.
[0175] INFORMATION RELATING TO A MICROORGANISM OR OTHER BIOLOGICAL MATERIAL DEPOSIT
[0176] (PCT rule 13Ws)
[0177] A. The indications relate to the microorganism or other biological material referred to in the description page / \Λ. , line / 46 .
[0178] B. DEPOSIT IDENTIFICATION Other deposits are subject to a separate sheet
[0179] Name of the deposit institution
[0180] NATIONAL COLLECTION OF CULTURES OF MICROORGANISMS (CNCM)
[0181] Address of the depositing institution (including postal code and country)
[0182] Pasteur Institute, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France
[0183] Filing date, order number
[0184] May 25, 2005 CNCM 1-3434
[0185] An additional sheet is attached.
[0186] C. ADDITIONAL INFORMATION (if applicable) for the continuation of this information
[0187] CERTIFICATE OF DEPOSIT.
[0188] D. DESIGNATED STATES FOR WHICH INDICATIONS ARE PROVIDED
[0189] (if the information is not provided for all designated states)
[0190] E. INFORMATION PROVIDED SEPARATELY (if applicable)
[0191] The information listed below will be provided later to the International Bureau (specify the general nature of the information, e.g., "n" of the filing order).
[0193] Form PCT / RO / 134 (July 1998; reprinted January 2004) Applicant's or agent's file reference: GBU / CLY / 070044 International Application No.
[0194] INFORMATION RELATING TO A MICROORGANISM OR OTHER BIOLOGICAL MATERIAL DEPOSIT
[0195] (PCT rule 130w)
[0198] Form PCT / RO / 134 (July 1998; reprinted January 2004) Applicant's or agent's file reference: GBU / CLY / 070044 International Application No.
[0199] INFORMATION RELATING TO A MICROORGANISM OR OTHER BIOLOGICAL MATERIAL DEPOSIT
[0200] (PCT Rule 136)
[0201] A. The indications relate to the microorganism or other biological material referred to in the description
[0202] B. DEPOSIT IDENTIFICATION Other deposits are subject to a separate sheet | |
[0203] Name of the deposit institution
[0204] NATIONAL COLLECTION OF CULTURES OF MICROORGANISMS (CNCM)
[0205] Address of the depositing institution (including postal code and country)
[0206] Pasteur Institute, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France
[0207] Filing date, order number
[0208] October 14, 2005 CNCM I-3504
[0209] An additional sheet is attached.
[0210] C. ADDITIONAL INFORMATION (if applicable) for the continuation of this information
[0211] CERTIFICATE OF DEPOSIT.
[0212] D. DESIGNATED STATES FOR WHICH INDICATIONS ARE PROVIDED
[0213] (if the information is not provided for all designated states)
[0214] E. INFORMATION PROVIDED SEPARATELY (if applicable)
[0215] The information listed below will be provided later to the International Bureau (specify the general nature of the information, e.g., "n" of the filing order).
[0217] PCT / RO / 134 Form (July 1998; reprinted January 2004) Applicant's or agent's file reference: GBU / CLY / 070044 International Application No.
[0218] INFORMATION RELATING TO A MICROORGANISM OR OTHER BIOLOGICAL MATERIAL DEPOSIT
[0219] (PCT rule 13)
[0220] A. The indications relate to the microorganism or other biological material referred to in the description on page .-A. &" > l'ë ne <&-(- ( - .
[0221] B. DEPOSIT IDENTIFICATION Other deposits are subject to a separate sheet | |
[0222] Name of the deposit institution
[0223] NATIONAL COLLECTION OF CULTURES OF MICROORGANISMS (CNCM)
[0224] Address of the depositing institution (including postal code and country)
[0225] Pasteur Institute, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France
[0226] Filing date, order number
[0227] October 14, 2005 CNCM I-3505
[0228] An additional sheet is attached.
[0229] C. ADDITIONAL INFORMATION (if applicable) for the continuation of this information
[0230] CERTIFICATE OF DEPOSIT.
[0231] D. DESIGNATED STATES FOR WHICH INDICATIONS ARE PROVIDED
[0232] (if the information is not provided for all designated states)
[0233] E. INFORMATION PROVIDED SEPARATELY (if applicable)
[0234] The information listed below will be provided later to the International Bureau (specify the general nature of the information, e.g., "n" of the filing order).
[0236] Form PCT / RO / 134 (July 1998; reprinted January 2004) Applicant's or agent's file reference: GBU / CLY / 070044 International Application No.
[0237] INFORMATION RELATING TO A MICROORGANISM OR OTHER BIOLOGICAL MATERIAL DEPOSIT
[0238] (PCT rule 130i.s)
[0241] PCT / RO / 134 Form (July 1998; reprinted January 2004)
Claims
Demands 1. A strain of Lactobacillus helveticus that does not have the ability to transform lactose into lactic acid.
2. A strain of Lactobacillus helveticus according to claim 1, possessing at least one mutation in the lactose operon.
3. A strain of Lactobacillus helveticus according to claim 2, possessing at least one point mutation introducing a stop codon into the lactose operon.
4. A Lactobacillus helveticus strain according to any one of claims 1-3, such that a dairy medium with 4.0% total protein containing 1.0% (w / w) glucose fermented by said Lactobacillus helveticus strain for a maximum fermentation time of 30h, at a temperature between 30 and 45°C, has a pH greater than or equal to 4.0, preferably greater than or equal to 4.
1.
5. A strain of Lactobacillus helveticus according to any one of claims 1-4, capable, by fermentation at a temperature between 30 and 450°C, more preferably between 32 and 43°C and even more preferably at 37°C of a milk medium containing an amount of glucose greater than 3% (w / w) and with a total protein content greater than or equal to 2% (w / w), preferably between 2 and 10% (w / w), more preferably between 2.5 and 6% and even more preferably equal to 4%, of producing the tripeptides of sequence IPP and / or VPP in an amount of at least 25 mg, preferably at least 50 mg, more preferably at least 75 mg of VPPeq per kg of fermented product.
6. A strain of Lactobacillus helveticus according to any one of claims 1-5, furthermore possessing a fructose-less phenotype.
7. Lactobacillus helveticus strain according to claim 1, selected from: 1-3504 filed with the CNCM on 14 / 10 / 05; 1-3505 filed with the CNCM on 14 / 10 / 05; 1-3508 filed with the CNCM on 14 / 10 / 05; and variant or mutant strains derived from these.
8. Use of a strain of Lactobacillus helveticus according to any one of claims 1-7, for the preparation of a food or pharmaceutical product, in particular a fermented dairy product.
9. Use according to claim 8, such that said food or pharmaceutical product has anti-hypertensive properties.
10. Food product, in particular fermented dairy product, comprising at least one strain of Lactobacillus helveticus according to one of the claims 1-7.
11. Food product according to claim 10, containing at least 106, preferably at least 107, preferably at least 108 CFU / mL of live Lactobacillus helveticus bacteria.
12. Food product according to any one of claims 10-11, containing at least 25 mg, preferably at least 50 mg, more preferably at least 75 mg of VPPeq per kg of said food product.
13. Food product according to any one of claims 10-12, further comprising fruit preparations, in particular pieces and / or fruit juice.
14. Food product according to any one of claims 10-13, having a pH greater than or equal to 3.85, preferably greater than or equal to 4.00, more preferably greater than or equal to 4.
20.
15. Food product according to any one of claims 10-14, which has anti-hypertensive properties.
16. A process for preparing a food product comprising the following steps: "select a raw material containing milk proteins, in particular proteins containing IPP peptide sequences and / or VPP; "select at least one Lactobacillus helveticus strain according to one of claims 1-7, " inoculate said raw material with said strain, " ferment said raw material in the presence of 1-3% (w / w) of glucose for 12-30 hours at 30-45°C, and in the presence of said strain.
17. Process according to claim 16, devoid of any thermization step after fermentation.
18. Use of streptozotocin to obtain Lactobacillus helveticus strains with a lactose-less phenotype.
19. A process for obtaining Lactobacillus helveticus strains possessing a lactose-negative phenotype, comprising the following steps: "provide at least one strain of Lactobacillus helveticus; "contact said at least one strain with an effective amount of streptozotocin in the presence of lactose; "isolate the colony or colonies of lactose-less phenotype.
20. A method according to claim 19, comprising a colorimetric test step on a medium containing Xgal and / or Sgal and / or any other compound linked by a β-galactosidic bond to galactose and which becomes detectable following the breaking of this bond by said strain of Lactobacillus helveticus.
